Skip to main content
Figure 2 | Breast Cancer Research

Figure 2

From: The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Figure 2

Breast cancer survival and distant recurrence-free survival in the Stockholm 2 patient cohort in relation to S6K1, S6K2 and 4EBP1 mRNA levels. Kaplan–Meier curves and multivariate Cox regression of breast cancer survival (BCS) and distant recurrence-free survival (DRFS) in the Stockholm 2 patient cohort, in relation to (a) p70 ribosomal S6 kinase 1 (S6K1) mRNA, (b) p70 ribosomal S6 kinase 2 (S6K2) mRNA, (c) 4E-binding protein 1 (4EBP1) mRNA, and (d) 4EBP1 mRNA in the oestrogen receptor alpha (ER)-positive subgroup. The Cox analysis included the following variables: adjuvant chemotherapy treatment, endocrine treatment, lymph node status, tumour size, and ER status. CI, confidence interval; HR, hazard ratio.

Back to article page